Skip to main content
AmigoFish

Jefferies London 2026: Valneva CEO Thomas Lingelbach shares an update on the status of the company's Lyme disease program (partnered with Pfizer) and more pipeline projects

From BiotechTV - News · · 12 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

He discusses the regulatory status of Lyme disease, which hit on secondary enpoints in its phase three trial but narrowly missed the primary. Plus, updates on chikungunya and shigella.

Back to BiotechTV - News · Report a problem